Skip to main content
Clinical Trials/NCT05964374
NCT05964374
Not yet recruiting
Not Applicable

Goal-Directed Therapy (GDT) Using Hypotension Prediction Index (HPI) Following Cardiac Surgery: a Pilot Randomized Control Trial

University of Calgary0 sites100 target enrollmentJuly 2023
ConditionsSurgery

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Surgery
Sponsor
University of Calgary
Enrollment
100
Primary Endpoint
24-hour cumulative IV fluid administration
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

Pilot prospective randomized control trial comparing goal-directed therapy algorithm vs routine care in the intensive care unit following cardiac surgery.

Detailed Description

Rationale: Goal-directed therapy (GDT) has been shown to reduce complications and length of stay on cardiac surgery patients. Unfortunately, the existing literature on GDT in CV surgery has several limitations, which creates uncertainty over the expected benefit of implementing this care element with high associated costs and impact on workflow. Hypotension Prediction Index (HPI) is a proprietary algorithm that utilizes pulse contour analysis from invasive arterial pressure monitoring to identify patients at risk for becoming hypotensive within 15 minutes. The algorithm was developed using machine learning on a large surgical/ICU data set, and then externally validated on non-cardiac and cardiac surgical patients. HPI, as part of a GDT algorithm, may allow healthcare providers to identify patients recovering from cardiac surgery who may benefit from optimization prior to becoming hypotensive and assist with selecting the most appropriate hemodynamic intervention. Hypothesis: Application of an HPI-based GDT algorithm will result in a difference in cumulative fluid administration over the first 24-hours of index ICU admission following cardiac surgery. Study Design: Unblinded randomized controlled trial pilot. Data will be used to inform/justify the feasibility, design, and implementation of a future multi-center randomized controlled trial. Study Population: Moderate or high-risk (EuroSCORE II \> 2%), non-emergent, adult open-heart cardiac surgery patients. Heart transplant, durable VAD implantation, or patients who require post-operative MCS support will be excluded. Sample size= 100 (50 control : 50 intervention) Intervention: Patients randomized to the intervention arm will be monitored using the HPI technology and be treated following a GDT algorithm when HPI is \>50 for 48-hours or duration of invasive arterial monitoring (whichever occurs first). The GDT algorithm is a standardized approach to identifying abnormal hemodynamic parameters and administering a prescribed therapy in a step-wise fashion with fixed re-assessment intervals (see attached). What will be different from routine care? : 1. Hemodynamic interventions (fluid, inotropic, or vasopressor therapy) will be administered when HPI \> 50 rather than MAP \< 65. 2. Choice of applied therapy (fluid, inotropic, or vasopressor therapy) will be guided by a GDT algorithm.

Registry
clinicaltrials.gov
Start Date
July 2023
End Date
June 2024
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • ≥ 18 years of age
  • Planned cardiac surgery using cardiopulmonary bypass (sternotomy or MICS)
  • Preoperative European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) of 2% or more.
  • Informed consent obtained.

Exclusion Criteria

  • Patients who refuse participation
  • Patients who are unable to give informed consent
  • Patients who are having a heart transplant or having surgery solely for an insertion of a ventricular assist device
  • Emergency surgery
  • Patients who require MCS (including ECMO, Impella, or IABP) post-operatively

Outcomes

Primary Outcomes

24-hour cumulative IV fluid administration

Time Frame: 24-hours

Cumulative post-operative intravenous fluid administration over the first 24-hours of index ICU admission.

Secondary Outcomes

  • Study Protocol Compliance(1-year)
  • Vasoactive medication administration(Duration of ICU stay, up to 30-days)
  • Enrollment(1-year)
  • Arterial Monitoring Reliability(1-year)
  • End-organ dysfunction/injury(Index admission, up to 30-days)
  • Transfusion(Index admission, up to 30-days)
  • Mobilzation(Index admission, up to 30-days)
  • Mobilization(Index admission, up to 30-days)
  • Hydration(Index admission, up to 30-days)
  • Fluid Administration(Duration of ICU stay, up to 30-days)
  • Length of Stay(Up to 1-year post-operative)
  • Hemodynamic parameters(48-hours or when arterial line removed)
  • Mortality(Up to 1-year post-operative)
  • GDT algorithm compliance(48-hours or when arterial line removed)
  • Nutrition(Index admission, up to 30-days)
  • Patient-centered Outcome(30-days)
  • Re-admission(30-days)

Similar Trials